Tags

Type your tag names separated by a space and hit enter

Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.
Clin Pharmacokinet 2013; 52(12):1045-61CP

Abstract

Since antiepileptic drugs (AEDs) are prescribed to treat various non-epilepsy-related disorders in addition to the fact that patients with epilepsy may develop concurrent disorders that will need treatment, the propensity for AEDs to interact with non-AEDs is considerable and indeed can present a difficult clinical problem. The present review details the pharmacokinetic and pharmacodynamic interactions that have been reported to occur with the new AEDs (eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, retigabine (ezogabine), rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide) and drugs used to treat non-epilepsy disorders. Interaction study details are described, as necessary, so as to allow the reader to take a view as to the possible clinical significance of particular interactions. Pharmacokinetic interactions relate to hepatic enzyme induction or inhibition and involved a variety of drugs including psychoactive drugs, cardioactive drugs, oral contraceptives, antituberculous agents, analgesics and antineoplastic drugs. A total of 68 pharmacokinetic interactions have been described, with lamotrigine (n = 22), topiramate (n = 18) and oxcarbazepine (n = 7) being associated with most, whilst lacosamide, pregabalin, stiripentol and vigabatrin are associated with none. Overall, only three pharmacodynamic interactions have been described and occur with oxcarbazepine, perampanel and pregabalin.

Authors+Show Affiliations

Department of Clinical and Experimental Epilepsy, Institute of Neurology, UCL, Queen Square, London, WC1N 3BG, UK, p.patsalos@ucl.ac.uk.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23794036

Citation

Patsalos, Philip N.. "Drug Interactions With the Newer Antiepileptic Drugs (AEDs)--Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-epilepsy Disorders." Clinical Pharmacokinetics, vol. 52, no. 12, 2013, pp. 1045-61.
Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52(12):1045-61.
Patsalos, P. N. (2013). Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clinical Pharmacokinetics, 52(12), pp. 1045-61. doi:10.1007/s40262-013-0088-z.
Patsalos PN. Drug Interactions With the Newer Antiepileptic Drugs (AEDs)--Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-epilepsy Disorders. Clin Pharmacokinet. 2013;52(12):1045-61. PubMed PMID: 23794036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. A1 - Patsalos,Philip N, PY - 2013/6/25/entrez PY - 2013/6/25/pubmed PY - 2014/7/9/medline SP - 1045 EP - 61 JF - Clinical pharmacokinetics JO - Clin Pharmacokinet VL - 52 IS - 12 N2 - Since antiepileptic drugs (AEDs) are prescribed to treat various non-epilepsy-related disorders in addition to the fact that patients with epilepsy may develop concurrent disorders that will need treatment, the propensity for AEDs to interact with non-AEDs is considerable and indeed can present a difficult clinical problem. The present review details the pharmacokinetic and pharmacodynamic interactions that have been reported to occur with the new AEDs (eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, retigabine (ezogabine), rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide) and drugs used to treat non-epilepsy disorders. Interaction study details are described, as necessary, so as to allow the reader to take a view as to the possible clinical significance of particular interactions. Pharmacokinetic interactions relate to hepatic enzyme induction or inhibition and involved a variety of drugs including psychoactive drugs, cardioactive drugs, oral contraceptives, antituberculous agents, analgesics and antineoplastic drugs. A total of 68 pharmacokinetic interactions have been described, with lamotrigine (n = 22), topiramate (n = 18) and oxcarbazepine (n = 7) being associated with most, whilst lacosamide, pregabalin, stiripentol and vigabatrin are associated with none. Overall, only three pharmacodynamic interactions have been described and occur with oxcarbazepine, perampanel and pregabalin. SN - 1179-1926 UR - https://www.unboundmedicine.com/medline/citation/23794036/Drug_interactions_with_the_newer_antiepileptic_drugs__AEDs___Part_2:_pharmacokinetic_and_pharmacodynamic_interactions_between_AEDs_and_drugs_used_to_treat_non_epilepsy_disorders_ L2 - https://dx.doi.org/10.1007/s40262-013-0088-z DB - PRIME DP - Unbound Medicine ER -